Ingenium Therapeutics
PrivateLast Round
Series A
Nov 21, 2023
Total Funding Raised
$8.91M
Company Overview
Ingenium Therapeutics operates in Healthcare & Life Sciences and is based in Daejeon. Its latest recorded funding round was a Series A round in November 2023.
Ingenium Therapeutics is a biotechnology company that develops next-generation cancer therapies based on innate immunity and NK cells for treatments of leukemia and solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ingenium Therapeutics Comparables
Compare Ingenium Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cure Genetics | 81% | |
| Arovella Therapeutics Ltd | 79% | |
| BrightPath Biotherapeutics Co., Ltd. | 78% |
For institutional investors. Book with your work email.
Ingenium Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 21, 2023 | ||||
| Pre Seed | Apr 1, 2022 |
For institutional investors. Book with your work email.
Ingenium Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K-Ground Ventures | Series A |
| Daewoodang Healthcare | Series A |
| Capstone Partners Korea | Series A |
| Laplace Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 21, 2023
$4.05M round led by Capstone Partners Korea.
- Apr 1, 2022
$4.86M raised in Pre Seed round.
For institutional investors. Book with your work email.
Ingenium Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ingenium Therapeutics's valuation, stock price, and market status.
Is Ingenium Therapeutics a public or private company?
Ingenium Therapeutics is a private company.
What is the current stock price of Ingenium Therapeutics?
Ingenium Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ingenium Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ingenium Therapeutics worth (valuation)?
Valuation information for Ingenium Therapeutics is not publicly available.
Can I buy Ingenium Therapeutics stock?
Ingenium Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ingenium Therapeutics's last funding round?
Ingenium Therapeutics's most recent funding round was Series A on November 21, 2023.
Who are the main investors in Ingenium Therapeutics?
Key investors in Ingenium Therapeutics include K-Ground Ventures, Daewoodang Healthcare, Capstone Partners Korea, Laplace Partners.
Will Ingenium Therapeutics IPO soon?
No public IPO plans have been announced for Ingenium Therapeutics.
How can I track Ingenium Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ingenium Therapeutics's shares on secondary markets.